Neoadjuvant chemotherapy in the management of advanced epithelial ovarian cancer

References

• Jemal A, Siegel R, Ward W et al. Cancer statistics. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N. Engl. J. Med.351, 2519–2529 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynoecia16, 585–596 (2002).
   PubMedGoogle Scholar
• Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer71(Suppl. 4), 1534–1540 (1993).
   PubMed Web of Science ®Google Scholar
• Omura GA, Bundy BN, Berek JS et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.7, 457–465 (1989).
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol.69, 103–108 (1998).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol.47, 159–166 (1992).
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Huh LJ et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol.103, 559–564 (2006).
   PubMed Web of Science ®Google Scholar
• Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Natl Cancer Inst. Monogr.45, 101–104 (1975).
   Google Scholar
• Hoskins WJ, McGuire WP, Bundy BN et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol.170, 974–979 (1994).
   PubMed Web of Science ®Google Scholar
• Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol.166, 504–511 (1992).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol.20, 1248–1259 (2002).
   PubMed Web of Science ®Google Scholar
• Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur. J. Gynaecol. Oncol.16, 349–356 (1995).
   PubMedGoogle Scholar
• Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer92, 2585–2591 (2001).
   PubMed Web of Science ®Google Scholar
• Kayikçiog L, Köse MF, Boran N et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer11, 466–470 (2001).
   Google Scholar
• Loizzi V, Cormio G, Resta L et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int. J. Gynecol. Cancer15, 217–223 (2005).
   Google Scholar
• Chi DS, Franklin CC, Levine DA et al. Improved optimal cytoreduction rates in Stage IIIC and IV epithelial ovarian, fallopian tube and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol.94, 650 (2004).
   PubMedGoogle Scholar
• Aletti GD, Gostout BS, Podratz KC et al. Ovarian cancer surgical respectability: relative impact of disease, patient status, and surgeon. Gynecol. Oncol.100, 33–37 (2006).
   PubMedGoogle Scholar
• Eisenkop SM, Spirto NM, Lin WC. “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol.103, 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• Crawford SC, Vasey PA, Paul J et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J. Clin. Oncol.23, 8802–8811 (2005).
   PubMedGoogle Scholar
• Crawford SC, Paul J, Kaye SB et al. Aggressive surgery and ovarian cancer. J. Clin. Oncol.24, 2398–2399 (2006).
   Google Scholar
• Neijt JP. Interval cytoreduction in ovarian cancer. N. Engl. J. Med.333, 254–255 (1995).
   PubMedGoogle Scholar
• van der Burg ME, Vergote I, Gynecologic Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Curr. Oncol. Rep.6, 473–481 (2003).
   Google Scholar
• Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced stage ovarian carcinoma. N. Engl. J. Med.351, 2489–2497 (2004).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med.334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol.72, 93–99 (1999).
   PubMed Web of Science ®Google Scholar
• Hou JY, Kelly MG, Yu H et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol. Oncol.105(1), 211–217 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer92, 2585–2591 (2001).
   PubMed Web of Science ®Google Scholar
• Onnis A, Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur. J. Gynaecol. Oncol.17, 393–396 (1996).
   PubMedGoogle Scholar
• Lee SJ, Kim BG, Lee JW et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J. Obstet. Gynaecol. Res.32, 99–106 (2006).
   PubMedGoogle Scholar
• Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol.71, 431–436 (1998).
   PubMed Web of Science ®Google Scholar
• Morice P, Dubernard G, Rey A et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg.197, 955–963 (2003).
   PubMedGoogle Scholar
• Sidney S, Chen, MD, Bouchner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol. Oncol.20, 190–195 (1985).
   PubMedGoogle Scholar
• Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol. Oncol.53, 326–330 (1994).
   PubMed Web of Science ®Google Scholar
• Michel G, De Iaco P, Castaigne D et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur. J. Gynaecol. Oncol.18, 9–15 (1997).
   PubMedGoogle Scholar
• Donato D, Angelides A, Irani H et al. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol. Oncol.44, 40–47 (1992).
   PubMedGoogle Scholar
• Kuhn W, Florack G, Roder J et al. The effect of upper abdominal surgeries on peri-operative morbidity and mortality in patients with advanced ovarian cancer FIGO III and IV. Int. J. Gynecol. Cancer8, 56–63 (1998).
   Web of Science ®Google Scholar
• Shibata K, Kikkawa F, Milka M. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int. J. Gynecol. Cancer13, 587–592 (2003).
   PubMedGoogle Scholar
• Hegazy MA, Hegazi RA, Elshafei MA et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J. Surg. Oncol.3, 57 (2005).
   PubMedGoogle Scholar
• Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case–control study. Eur. J. Gynaecol. Oncol.23, 405–410 (2002).
   PubMedGoogle Scholar
• Mazzeo F, Berliere M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable advanced-stage ovarian cancer. Gynecol. Oncol.90, 163–169 (2003).
   PubMed Web of Science ®Google Scholar
• Surwit E, Childers J, Atlas I et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int. J. Gynecol. Cancer6, 356–366 (1996).
   Web of Science ®Google Scholar
• Le T, Faught W, Hopkins L et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced stage epithelial ovarian cancer. Int. J. Gynecol. Cancer15, 770–775 (2005).
   PubMedGoogle Scholar
• Ivanov S, Ivanov S, Khadzhiolov N. Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy. Akush Ginekol. (Sofiia)43, 17–19 (2004).
   PubMedGoogle Scholar
• Inciura A, Simavicius A, Juozaityte E. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced stage ovarian cancer: a retrospective study of 574 patients. BMC Cancer6, 153 (2006).
   PubMedGoogle Scholar
• Steed H, Oza AM, Murphy J et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer.16, 47–53 (2006)
   PubMedGoogle Scholar
• Bidzinski M, Danska-Bridzinska A, Ziolkowska-Seta I et al. Analysis of the treatment of ovarian cancer patients with neoadjuvant chemotherapy – preliminary results. Eur. J. Gynaecol. Oncol.26, 423–426 (2005).
   PubMedGoogle Scholar
• Shimizu Y, Hasumi K. Treatment of ovarian cancer at FIGO stage III and IV – prognostic factors for patients receiving neoadjuvant chemotherapy. Nippon Sanka Fujinka Gakkai Zasshi45, 665–672 (1993).
   PubMedGoogle Scholar
• Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer91, 2329–2334 (2001).
   PubMed Web of Science ®Google Scholar
• Elit L, Chartier C, Oza A et al. Outcomes for systemic therapy in women with ovarian cancer. Gynecol. Oncol.103, 554–558 (2006).
   PubMedGoogle Scholar
• Chi DS, Venkatraman ES, Masson V et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian cancer. Gynecol. Oncol.77, 227–231 (2000).
   PubMed Web of Science ®Google Scholar
• Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol. Obstet. Invest.57, 153–156 (2004).
   PubMedGoogle Scholar
• Pfisterer J, Harter P, Canzler U et al. The role of surgery in recurrent ovarian cancer. Int. J. Gynecol. Cancer25, 195–198 (2005).
   Google Scholar
• Schwartz PE, Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol. Oncol.90, 644–650 (2003).
   PubMedGoogle Scholar
• Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol.11, 166–172 (1993).
   PubMed Web of Science ®Google Scholar
• Qayyum A, Coakley FV, Westphalen AC et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol.96, 301–306 (2005).
   PubMed Web of Science ®Google Scholar
• Axtell AE, Lee MH, Bristow RE et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol.25, 384–389 (2007).
   PubMedGoogle Scholar
• Vergote I, de Wever I, Tjalma W et al. Interval debulking surgery: an alternative to primary surgical debulking? Semin. Surg. Oncol.19, 49–53 (2000).
   PubMedGoogle Scholar
• Fagotti A, Fanfani F, Ludovisi M et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol. Oncol.96, 729–735 (2005).
   PubMed Web of Science ®Google Scholar
• Deffieux X, Castaigne D, Pomer C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int. J. Gynecol. Cancer16(Suppl. 1), 35–40 (2006).
   PubMedGoogle Scholar
• Guppy AE, Nathan PD, Rustin GJ et al. Epithelial ovarian cancer: a review of current management. Clin. Oncol.17, 399–411 (2005).
   PubMed Web of Science ®Google Scholar